Asia Pacific Biotech Developing Inc.

Kaohsiung, Taiwan

Asia Pacific Biotech Developing Inc.

Kaohsiung, Taiwan
SEARCH FILTERS
Time filter
Source Type

Patent
Asia Pacific Biotech Developing Inc. | Date: 2016-07-28

The present invention relates to a method for adjunctive treatment of cancer by using a Lycogen composition to inhibit metastasis, comprising administering a Lycogen composition to the subject, wherein the Lycogen composition comprises an effective amount of a Lycogen extract, wherein the Lycogen extract comprises active ingredients selected from -carotene, neurosporene, spheroidenone, methoxyneurosporene or a combination thereof.


Liu W.-S.,Asia Pacific Biotech Developing Inc. | Kuan Y.-D.,China Medical University at Taichung | Chiu K.-H.,National Kaohsiung Marine University | Wang W.-K.,Feng Chia University | And 4 more authors.
Marine Drugs | Year: 2013

Reducing hyperpigmentation has been a big issue for years. Even though pigmentation is a normal mechanism protecting skin from UV-causing DNA damage and oxidative stress, it is still an aesthetic problem for many people. Bacteria can produce some compounds in response to their environment. These compounds are widely used in cosmetic and pharmaceutical applications. Some probiotics have immunomodulatory activities and modulate the symptoms of several diseases. Previously, we found that the extracts of Rhodobacter sphaeroides (Lycogen™) inhibited nitric oxide production and inducible nitric-oxide synthase expression in activated macrophages. In this study, we sought to investigate an anti-melanogenic signaling pathway in α-melanocyte stimulating hormone (α-MSH)-treated B16F10 melanoma cells and zebrafish. Treatment with Lycogen™ inhibited the cellular melanin contents and expression of melanogenesis-related protein, including microphthalmia-associated transcription factor (MITF) and tyrosinase in B16F10 cells. Moreover, Lycogen™ reduced phosphorylation of MEK/ERK without affecting phosphorylation of p38. Meanwhile, Lycogen™ decreased zebrafish melanin expression in a dose-dependent manner. These findings establish Lycogen™ as a new target in melanogenesis and suggest a mechanism of action through the ERK signaling pathway. Our results suggested that Lycogen™ may have potential cosmetic usage in the future. © 2013 by the authors; licensee MDPI.


Mong F.-Y.,ZuoYing Armed Forces General Hospital | Kuo Y.-L.,Chung Shan Medical University | Liu C.-W.,I - Shou University | Liu W.-S.,Asia Pacific Biotech Developing Inc. | Chang L.-C.,I - Shou University
Molecular Biology Reports | Year: 2011

Given the essential role of prolactin (PRL) and its receptor (PRLR) in breast tumorigenesis, we investigated whether single nucleotide polymorphisms (SNPs) in the PRL and PRLR genes were associated with breast cancer in Taiwanese women. A total of 160 breast cancer patients and 336 unrelated control Taiwanese women were enrolled in this study. Three SNPs (rs1341238, rs2244502 and rs3756824) in the PRL gene and one SNP (rs10941235) in the PRLR gene were genotyped using allele-specific polymerase chain reaction and DNA sequencing. We showed that the PRLR SNP rs10941235 was associated with breast cancer (P < 0.05) and its genotype frequencies in the breast cancer group were significantly associated (P < 0.05) with the levels of cancer antigen 15-3, a serum biomarker of breast cancer. The PRL SNP rs3756824 was significantly associated with breast cancer metastasis (P < 0.05). These findings suggest that the polymorphism rs10941235 in the PRLR gene is associated with breast cancer and cancer antigen 15-3 levels in Taiwanese women. © 2010 Springer Science+Business Media B.V.


Liu W.-S.,National Sun Yat - sen University | Liu W.-S.,Asia Pacific Biotech Developing Inc. | Chen M.-C.,China Medical University at Taichung | Chiu K.-H.,National Kaohsiung Marine University | And 2 more authors.
Molecules | Year: 2012

Bacteria can produce some compounds in response to their environment. These compounds are widely used in cosmetic and pharmaceutical applications. Some probiotics have immunomodulatory activities and modulate the symptoms of several diseases. Autoimmune diseases represent a complex group of conditions that are thought to be mediated through the development of autoreactive immunoresponses. Inflammatory bowel disease (IBD) is common autoimmune disease that affects many individuals worldwide. Previously, we found that the extracts of Rhodobacter sphaeroides (Lycogen) inhibited nitric oxide production and inducible nitric-oxide synthase expression in activated macrophages. In this study, the effect of Lycogen™, a potent anti-inflammatory agent, was evaluated in mice with dextran sodium sulfate (DSS)-induced colitis. Oral administration of Lycogen™ reduced the expressions of proinflammatory cytokines (tumor necrosis factor-α and interleukin-1β) in female BABL/c mice. In addition, the increased number of bacterial flora in the colon induced by DSS was amelirated by Lycogen™. The histological score of intestinal inflammation in 5% DSS-treated mice after oral administration of Lycogen™ was lower than that of control mice. Meanwhile, Lycogen™ dramatically prolonged the survival of mice with severe colitis. These findings identified that Lycogen™ is an anti-inflammatory agent with the capacity to ameliorate DSS-induced colitis. © 2012 by the authors.


Wun W.-T.,Yung Ta Institute of Technology and Commerce | Liu W.-S.,Asia Pacific Biotech Developing Inc.
Advanced Materials Research | Year: 2011

A Rhodobacter sphaeroides WL-APD911 with the capability of producing the end products of neurosporene and ξ-carotene, rather than the normal end products of spheroidene, was isolated from hundreds of strains by using chemical mutagenesis. The strain WL-APD911 grew well in LB medium, and the colored carotenoids were produced within 3 days of incubation at 30°C. The Rs-M of colored carotenoid extracts obtained from strain WL-APD911 by using methanol extraction inhibited the NO production and iNOS expression by LPS-induced RAW 264.7 cells. This probability of reason for the Rs-M as the best source was to prompt the anti-inflammation and anti-oxidation in nutraceutical products. Finally, the carotenoid extracts (Rs-M) with neurosporene and ξ-carotene was called lycogene to be a newly biomaterial. © (2011) Trans Tech Publications.


Chiu K.-H.,National Kaohsiung Marine University | Liu W.-S.,National Kaohsiung Marine University | Liu W.-S.,Asia Pacific Biotech Developing Inc.
Aquaculture | Year: 2014

A commercial carotenoid product from the extract of probiotic Rhodobacter sphaeroides mutant strain WL-APD911 (Lycogen™) contains neurosporene, ξ-carotene, spheroidenone and methoxyneurosporene rather than lycopene. In the present study, Lycogen™ was used to improve the growth performance of seawater red tilapia (Oreochromis mossambicus×Oreochromis niloticus) for 7weeks. The results showed that dietary supplementation with 1.0% Lycogen™ in seawater tilapia did not cause changes in body length but significantly increased muscle weight, weight gain, the specific growth rate (SGR) and the feed conversion ratio (FCR). Because there were no intergroup differences in the proximate composition of the fish muscle, the increased body weight of Lycogen™-supplemented tilapia might have resulted from muscle growth instead of changes in muscle composition. An analysis of the expression levels of growth-associated genes, i.e., growth hormone receptor 1 (GHR1) and insulin growth factor-1 (IGF-1), showed that an alternative splicing form of GHR1 accumulated to a significant extent in the muscle of tilapia fed with a Lycogen™-supplemented diet. In addition, innate humoral responses, reflected by lysozyme activity and alternative complement activity (ACH50), also significantly increased in the sera of Lycogen™-treated tilapia. The present study suggests a potential application of the biomaterial Lycogen™ in the aquaculture field: to enhance tilapia growth performance via immune regulation. © 2013 Elsevier B.V.


Chang W.-W.,Chung Shan Medical University | Liu J.-J.,China Medical University at Taichung | Liu C.-F.,China Medical University at Taichung | Liu W.-S.,Asia Pacific Biotech Developing Inc. | And 4 more authors.
Toxins | Year: 2013

Cisplatin is used as a treatment for various types of solid tumors. Renal injury severely limits the use of cisplatin. Renal cell apoptosis, oxidative stress, and inflammation contribute to cisplatin-induced nephrotoxicity. Previously, we found that an extract of Rhodobacter sphaeroides (Lycogen™) inhibited proinflammatory cytokines and the production of nitric oxide in activated macrophages in a dextran sodium sulfate (DSS)-induced colitis model. Here, we evaluated the effect of Lycogen™, a potent anti-inflammatory agent, in mice with cisplatin-induced renal injury. We found that attenuated renal injury correlated with decreased apoptosis due to a reduction in caspase-3 expression in renal cells. Oral administration of Lycogen™ significantly reduced the expression of tumor necrosis factor-α and interleukin-1β in mice with renal injury. Lycogen™ reduces renal dysfunction in mice with cisplatin-induced renal injury. The protective effects of the treatment included blockage of the cisplatin-induced elevation in serum urea nitrogen and creatinine. Meanwhile, Lycogen™ attenuated body weight loss and significantly prolonged the survival of mice with renal injury. We propose that Lycogen™ exerts anti-inflammatory activities that represent a promising strategy for the treatment of cisplatin-induced renal injury. © 2013 by the authors; licensee MDPI, Basel, Switzerland.


PubMed | National Chung Hsing University, China Medical University at Taichung, National Sun Yat - sen University, National Kaohsiung Marine University and 3 more.
Type: | Journal: BioMed research international | Year: 2017

Bladder cancer is one of the major cancer types and both environmental factors and genetic background play important roles in its pathology. Kaohsiung is a high industrialized city in Taiwan, and here we focused on this region to evaluate the genetic effects on bladder cancer. Muscarinic acetylcholine receptor M3 (CHRM3) was reported as a key receptor in different cancer types.


PubMed | Asia Pacific Biotech Developing Inc., University of Delaware and National Kaohsiung Marine University
Type: | Journal: Chemosphere | Year: 2016

The characteristics of nanoparticles (NPs) uptake may fundamentally alter physicochemical effects of engineered NPs on aquatic organisms, thereby yielding different ecotoxicology assessment results. The adsorption behavior of nano-TiO2 (P-25) on zebrafish embryos in Holtfreters medium (pH 7.2, I7.210(-2)M) and the presence of sodium alginate (100mg/L) as dispersant was investigated. Zebrafish embryos (total 100) were exposed to nano-TiO2 at different concentrations (e.g., 0, 10, 20, 60, 120mg/L) in batch-mode assay. The adsorption capacity of nano-TiO2 on fish eggs was determined by measuring the Ti concentration on the egg surface using ICP-OES analysis. Results showed that the adsorption capacity increased rapidly in the first hour, and then declined to reach equilibrium in 8h. The adsorption characteristics was visualized as a three-step process of rapid initial layer formation, followed by break-up of aggregates and finally rearrangement of floc structures; the maximum adsorption capacity was the sum of an inner rigid layers of aggregates of 0.81-0.84g-TiO2/#-egg and an outer softly flocculated layers of 1.01g-TiO2/#-egg. The Gibbs free energy was 543.29-551.26 and 100.75kJ/mol, respectively, for the inner-layer and the outer-layer aggregates. Adsorption capacity at 0.5-1.0g-TiO2/#-egg promoted egg hatching; but hatching was inhibited at higher adsorption capacity. Results clearly showed that the configuration of TiO2 aggregates could impact the hatching efficiency of zebrafish embryos.


Patent
Asia Pacific Biotech Developing Inc. | Date: 2011-07-21

A lycogen extract comprising active ingredient of -carotene, neurosporene, spheroidenone and/or methoxyneurosporene is described. A composition comprising the lycogen extract of the present invention and food scientific or pharmaceutical acceptable carrier is also presented. A method for the treatment of disease in need of the lycogen extract which comprises administering to a patient in need thereof a therapeutically effective amount of lycogen extract of the present invention is further described.

Loading Asia Pacific Biotech Developing Inc. collaborators
Loading Asia Pacific Biotech Developing Inc. collaborators